Key result
Eprosartan significantly reduced platelet activation, microparticle formation, and calcium mobilization towards control values in patients with stage 1 or 2 hypertension.
Why the study?
Does eprosartan reduce platelet activation and microparticle formation in patients with stage 1 or stage 2 hypertension?
Does eprosartan reduce platelet activation and microparticle formation in patients with stage 1 or stage 2 hypertension?
Eprosartan reduces platelet activation and microparticle formation in hypertensive patients, suggesting a potential mechanism for reducing atherosclerotic event risk.
Should not yet change hypertension management; hypothesis-generating for eprosartan’s platelet effects on thrombotic risk.
The study examined a number of parameters of platelet function and activation in hypertensive patients compared with normotensive patients. It also examined the effects of the angiotensin receptor blocker eprosartan on these parameters. There were 30 patients with stage 1 or stage 2 hypertension plus 31 well-matched controls in this study. Phosphatidylserine, a measure of circulating activated platelets, was expressed more in hypertensive patients than in controls. Eprosartan partially corrected the enhanced platelet reactivity.There were greater numbers of activated platelet microparticles in hypertensive patients compared to controls. Again, eprosartan reduced this hyperproduction. Calcium kinetics of platelets were measured with flow cytometry using fluorescent markers.The free calcium concentration and its rise in response to thrombin were greater in hypertensive patients. Eprosartan significantly changed these parameters towards control values and reduced platelet activation. PATIENTS: Thus, eprosartan has the potential to reduce the risk of atherosclerotic events in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Marcial Martínez Silvestre (2005) studied Hypertension (n=61). Eprosartan vs. Normotensive controls was evaluated on Platelet function, activation, and calcium kinetics. Eprosartan significantly reduced platelet activation, microparticle formation, and calcium mobilization towards control values in patients with stage 1 or 2 hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: